Related Experiment Video
Updated: Oct 21, 2026
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
Immunologic effects of levamisole in mice and humans: evidence for augmented antibody response without modulation of
M A Tempero1, Y Haga, C Sivinski
1Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330, USA.
Abstract:
Selected immunomodulatory effects of levamisole were studied in patients with asymptomatic metastatic colon cancer and in a preclinical model (CF1 female mice treated with methyl-azoxymethanol acetate) for colon tumors. In the patient population studied, there was no augmentation of cellular cytotoxicity or alteration in lymphocyte subpopulations that participate in these functions. An increase in Fc receptor binding on circulating monocytes was apparent at the 4-week timepoint; however, a corresponding increase in antibody-dependent cellular cytotoxicity was observed in only one of the six patients studied. In most patients, cellular cytotoxicity diminished with time. No significant effects on cellular immunity or carcinogenesis were observed in our murine studies. However, treatment with levamisole did increase circulating immunoglobulin levels and IgM response in mice immunized with the T-dependent antigen keyhole limpet hemocyanin. This parameter was not tested in the human trial. Failure to demonstrate antitumor effects on cellular immunity by levamisole in both human and murine studies suggests that these effects, if they do exist, may involve immunological parameters that were not tested using our methods or that may not be apparent in patients with more advanced malignancy.
Insights
Levamisole showed limited immunomodulatory effects in colon cancer patients and mice. While it increased immunoglobulin levels in mice, it did not significantly enhance cellular immunity or demonstrate antitumor effects in either model.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Levamisole is an immunomodulatory agent with potential anticancer applications.
- Its effects on cellular immunity in colon cancer patients and preclinical models require further investigation.
Purpose of the Study:
- To evaluate the immunomodulatory effects of levamisole in patients with asymptomatic metastatic colon cancer.
- To assess levamisole's impact on cellular immunity and carcinogenesis in a preclinical mouse model.
Main Methods:
- Human study: Monitored cellular cytotoxicity, lymphocyte subpopulations, and Fc receptor binding in colon cancer patients treated with levamisole.
- Murine study: Evaluated levamisole's effects on cellular immunity, carcinogenesis, immunoglobulin levels, and antibody response in mice.
Main Results:
- In patients, levamisole did not augment cellular cytotoxicity or alter lymphocyte subpopulations; Fc receptor binding increased transiently, but antibody-dependent cellular cytotoxicity enhancement was minimal.
- Murine studies showed no significant effects on cellular immunity or carcinogenesis, but levamisole increased circulating immunoglobulin and IgM levels.
- Cellular cytotoxicity generally diminished over time in human patients.
Conclusions:
- Levamisole demonstrated limited immunomodulatory effects on cellular immunity in metastatic colon cancer patients and preclinical models.
- The observed increase in immunoglobulin levels in mice suggests potential B-cell involvement, which was not assessed in humans.
- Antitumor effects mediated by cellular immunity were not evident, suggesting potential involvement of untested immunological parameters or limitations in advanced disease.
More Related Videos
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
06:57Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
